We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
America’s towns and counties could be condensed into a single class to simplify the highly complex litigation against opioid drugmakers, a key plaintiff’s lawyer suggests. Read More
Amgen, Merck, Eli Lilly and the Association of National Advertisers have filed suit against HHS’ rule requiring drug companies to display list prices in TV ads, claiming the requirement will only sow confusion. Read More
“We cannot understand why Americans pay two to six times more than the rest of the world for brand name prescription drugs or why the U.S. comprised 42 percent of global pharmaceutical revenues…” the letter stated. Read More
A Dutch research institute believes oncology patients should be covered for treatments not intended for their type of cancer—if the off-label treatments work in trials—and it’s trying out performance-based payments. Read More
PhRMA and AARP are crossing swords over the Trump Administration’s proposed rule to require prescription drug rebates directly to customers at the pharmacy counter. Read More
Leaders of the House Energy & Commerce Committee sent letters on Thursday to the FDA and five other agencies asking for a briefing on the fentanyl crisis. Read More
The FDA has asked Merck to team up with IBM, KPMG and Walmart to put together a new pilot program testing whether blockchain can help regulators track and trace prescription drugs along the increasingly complex supply chain. Read More